As shown in Figure 2B, there were about 50 enriched metabolites in the tumor tissue of patients with estrogen receptor-negative (ER−) breast cancer when compared to tumor tissue of patients with estrogen receptor-positive (ER+) breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.